HRT plus GLP-1: what the 2026 Mayo Clinic data showed
In a retrospective study of 120 postmenopausal women taking tirzepatide, the 40 systemic hormone-therapy users had mean weight loss of 19.2%, versus 14.0% in 80 matched nonusers at the last follow-up, after a mean follow-up of about 18 months. The difference was 5.2 percentage points. The study was published online in January 2026 and in the February 2026 issue of The Lancet Obstetrics, Gynaecology, & Women’s Health. It shows an association, not that starting hormone therapy improves weight loss.
- What the 2026 Mayo Clinic and Lancet data actually measured
- Why menopause can blunt how weight responds to treatment
- Who the finding applies to, and who it does not
- The questions to bring to a clinician about combining the two
The 2026 data put a number on a real gap
A retrospective Mayo Clinic study found an association between systemic menopausal hormone therapy use and greater weight loss among postmenopausal women taking tirzepatide. It did not establish that starting hormone therapy causes additional weight loss.
Menopause changes how weight responds, and that is biology
A quick myth bust. Hormone therapy is a weight-loss treatment. It is not, and it is not approved or prescribed for that. It treats menopause symptoms. The 2026 finding is about how a GLP-1 performed alongside hormone therapy, not about hormones causing weight loss on their own.
The finding applies to a specific group, not everyone
This matters before you do anything with the number. The study looked at postmenopausal women already on a GLP-1, comparing those who were also on hormone therapy with those who were not. If you are premenopausal, or not a candidate for hormone therapy, the average does not map onto you. A clinician sorts out which group you are in.
How the two tools compare, side by side
Compounded medicines are not FDA-approved. Ask the prescriber and dispensing pharmacy why a compounded product is being considered, how it differs from an approved product, and what current requirements apply. A patient-specific prescription does not make a compounded medicine FDA-approved. 1.
| Hormone therapy | GLP-1 medication | |
|---|---|---|
| What it treats | Menopause symptoms (hot flashes, night sweats, vaginal symptoms) | Weight management and metabolic health |
| How it is decided | Symptoms, timing since menopause, full history | History, weight goals, other conditions |
| Is weight loss the goal? | No, it is not approved or prescribed for that | Yes, under a clinician's plan |
| Who decides | A licensed clinician, with you | A licensed clinician, with you |
What a careful provider should tell you first
Before you act on any headline number, hold your provider to a real standard. A good midlife-care provider, online or in person, separates the two questions, ties any recommendation to your history, and never sells a study average as your guaranteed outcome. They also show you every cost before your card is charged.
Your next three steps
A headline number is a starting point, not an answer. The decision deserves a clinician who knows your details and treats the study average as what it is: an average. Your job is to walk in ready. Now you are. For the bigger picture on weight in these years, see our hub on midlife metabolism and weight.
Explore your hormone therapy options
- Online evaluation by a licensed clinician
- Treatment based on your health and goals
- Clear pricing before you commit
From price shown is the 6-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Women's Health
Women's Health
Women's Health
Women's Health
Women's Health
Women's Health
Sources
- FDA. Human Drug Compounding. Current regulatory overview accessed September 15, 2026. fda.gov
- The Menopause Society. "The Menopause Society Comments on the FDA Announcement on Hormone Therapy." 2026. menopause.org
- FDA. "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products." February 12, 2026. fda.gov
- Mayo Clinic Press. "Explaining the stages of menopause." Accessed 2026. mcpress.mayoclinic.org
- Primary retrospective cohort on menopausal hormone therapy, tirzepatide and weight change. The Lancet Obstetrics, Gynaecology, & Women's Health, February 2026 issue. sciencedirect.com